Answers are grounded in this paper and cite their sources.
Li-Fraumeni syndrome (LFS) is primarily a childhood disease in families with inherited susceptibility due to germline TP53 variants that produce the signature tumours of this syndrome, namely adrenocortical carcinoma, choroid plexus tumours, embryonal rhabdomyosarcoma, sonic hedgehog-subgroup medulloblastoma and osteosarcoma, most diagnosed before 20 years of age.A cancer diagnosed in childhood significantly increases the probability of a second one later on.This mini-review will discuss pediatric-specific evidence regarding radiotherapy-and chemotherapy-associated second cancers among children with LFS, non-genotoxic and risk-reducing strategies currently available to them, as well as how decision making for an affected child differs from that for an adult carrying the same mutation-both biologically due to many remaining years of risk and practically in terms of consent disclosure and family dynamics issues rarely addressed with such depth in adult oncology.Genotoxic cancer treatment should not be withheld from a child suffering from an aggressive malignancy because of theoretical fears concerning complications of the treatment.However, it should be emphasized that the particular imaging technique, radiotherapy modality, and drug class must be selected very carefully.This is because any time left for any child can more realistically be measured in decades during which there exists a realistic possibility of developing a second cancer.
No takes yet. Share an insight, caveat, or question.
Ruggiero et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: